/ACHV
ACHV Stock - Achieve Life Sciences, Inc.
Healthcare|BiotechnologyNASDAQ
$4.32-0.46%
$0.02 (-0.46%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.72
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACHV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.28 – $4.36
TARGET (TP)$4.75
STOP LOSS$3.97
RISK/REWARD1:1.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.70
52W High$5.78
52W Low$1.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-229,000 | N/A | N/A | N/A | $-255,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-39,069,000 | $-27,250,000 | $-40,800,000 | $-33,094,000 | $-14,750,000 |
| Net Income | $-39,827,000 | $-29,815,000 | $-42,350,000 | $-33,152,000 | $-14,661,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.24 | $-1.50 | $-3.95 | $-4.05 | $-5.39 |
Company Overview
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
1
20%
Buy / Outperform
4
80%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 284.3% Upside
Now
$12
Low
$17
Average
$20
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Citizens JMP | Initiation | Mkt Outperform | $19 |
| August 21st 2025 | H.C. Wainwright | Initiation | Buy | $12 |
| November 14th 2024 | Rodman & Renshaw | Initiation | Buy | $12 |
| September 27th 2024 | Raymond James | Initiation | Strong Buy | $20 |
| May 10th 2023 | Maxim Group | Reiterated | Buy | $20← $8 |
Earnings History & Surprises
ACHVBeat Rate
28%
Last 18 quarters
Avg Surprise
-5.7%
EPS vs Estimate
Beats / Misses
5/10
3 met exactly
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
+18.8%
$-0.26vs$-0.32
Q2 24
-8.3%
$-0.26vs$-0.24
Q3 24
-13.6%
$-0.25vs$-0.22
Q4 24
-38.5%
$-0.36vs$-0.26
Q1 25
-20.0%
$-0.36vs$-0.30
Q2 25
0.0%
$-0.37vs$-0.37
Q3 25
0.0%
$-0.37vs$-0.37
Q4 25
-16.7%
$-0.28vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.37 | $-0.37 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.37 | $-0.37 | 0.0% | = MET |
Q1 2025 | Mar 11, 2025 | $-0.30 | $-0.36 | -20.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.26 | $-0.36 | -38.5% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.34 | $-0.34 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.41 | $-0.43 | -4.9% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.65 | $-0.50 | +23.1% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.90 | $-0.83 | +7.8% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-1.10 | $-1.35 | -22.7% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.79 | $-1.08 | -36.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.82 | $-0.80 | +2.4% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.73 | $-0.76 | -4.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-1.09 | $-0.71 | +34.9% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-1.23 | $-1.53 | -24.4% | ✗ MISS |
Latest News
Citizens Initiates Coverage On Achieve Life Sciences with Market Outperform Rating, Announces Price Target of $19
📈 PositiveBenzinga•Nov 25, 2025, 01:41 PM
Achieve Life Sciences Announces FDA Accepted Cytisinicline New Drug Application To Treat Nicotine Dependence; PDUFA Date Set For June 20, 2026
📈 PositiveBenzinga•Nov 6, 2025, 12:31 PM
Achieve Life Sciences Q3 EPS $(0.28) Misses $(0.26) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 12:07 PM
Achieve Life Sciences Announces Key NDA Milestones For Cytisinicline; Co Submits 120-Day Update To FDA; Concludes ORCA-OL Safety Trial; DSMC Finds No Safety Concerns For Cytisinicline
📈 PositiveBenzinga•Nov 3, 2025, 01:41 PM
Achieve Life Sciences shares are trading higher after the FDA awarded the company a Commissioner's National Priority Voucher for cytisinicline as a treatment of nicotine dependence for e-cigarette or vaping cessation.
📈 PositiveBenzinga•Oct 17, 2025, 01:26 PM
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher For Cytisinicline In E-Cigarette/Vaping Cessation—One Of Nine In Inaugural Program, Enabling 1–2 Month Expedited Review
📈 PositiveBenzinga•Oct 17, 2025, 11:33 AM
Achieve Life Sciences Publishes New Data In Thorax Entitled "Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials"
📈 PositiveBenzinga•Sep 22, 2025, 12:38 PM
Achieve Life Sciences Appoints Craig Donnelly To COO
➖ NeutralBenzinga•Sep 18, 2025, 12:32 PM
FDA Accepts Achieve Life Sciences' Cytisinicline New Drug Application For Treatment For Smoking Cessation In Adults.
📈 PositiveBenzinga•Sep 3, 2025, 12:32 PM
Achieve Life Sciences shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $12 price target.
📈 PositiveBenzinga•Aug 21, 2025, 03:36 PM
HC Wainwright & Co. Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Aug 21, 2025, 11:10 AM
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering
📉 NegativeSeeking Alpha•Jun 27, 2025, 07:11 AM
Achieve Life Sciences announces proposed public offering; shares down nearly 13%
📉 NegativeSeeking Alpha•Jun 26, 2025, 08:12 PM
Frequently Asked Questions about ACHV
What is ACHV's current stock price?
Achieve Life Sciences, Inc. (ACHV) is currently trading at $4.32 per share. The stock has moved -0.46% today.
What is the analyst price target for ACHV?
The average analyst price target for ACHV is $4.75, based on 1 analyst.
What sector is Achieve Life Sciences, Inc. in?
Achieve Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACHV's market cap?
Achieve Life Sciences, Inc. has a market capitalization of $0.23 billion, making it a small-cap company.
Does ACHV pay dividends?
No, Achieve Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to ACHV for comparison